# Extension 1: First Temporary Rule — DEA telemedicine controlled-substance prescribing flexibility -- extension history

For Extension 1: First Temporary Rule, published is 05/10/2023; federal register citation is 88 FR 30037; document number is 2023-09936; effective period as stated is This rule is effective May 11, 2023, through November 11, 2024; flexibility extended through is November 11, 2023, verified against its source on 2026-08-31.

- **Temporary rule:** Extension 1: First Temporary Rule _(our reading, not quoted from the source)_
- **Published:** 05/10/2023 _(verified: appears in the quote below)_
- **Federal Register citation:** 88 FR 30037 _(verified: appears in the quote below)_
- **Document number:** 2023-09936 _(verified: appears in the quote below)_
- **Effective period as stated:** This rule is effective May 11, 2023, through November 11, 2024. _(verified: appears in its own passage below)_
- **Flexibility extended through:** November 11, 2023 _(verified: appears in its own passage below)_
- **Longer extension for a narrower group:** through November 11, 2024, but only with respect to patients with whom the prescribing practitioner has a telemedicine relationship established via COVID-19 telemedicine prescribing flexibilities on or before November 11, 2023 _(verified: appears in its own passage below)_

## What the source says

> A Rule by the Drug Enforcement Administration and the Health and Human Services Department on 05/10/2023 Published Document: 2023-09936 (88 FR 30037)

## Where each value comes from

This source states these in separate places, so each value is shown with the passage that states it.

### Effective period as stated

> DATES: This rule is effective May 11, 2023, through November 11, 2024.

### Flexibility extended through

> Paragraph (c) extends the COVID-19 telemedicine prescribing flexibilities for six months, from May 12, 2023 through November 11, 2023, provided all of the conditions listed in paragraph (e) are met.

### Longer extension for a narrower group

> Paragraph (d) provides for a partial extension of those telehealth flexibilities through November 11, 2024, but only with respect to patients with whom the prescribing practitioner has a telemedicine relationship established via COVID-19 telemedicine prescribing flexibilities on or before November 11, 2023, as defined in paragraph (b) and provided all the conditions listed in paragraph (e) are met.

## Source

- https://www.federalregister.gov/documents/2023/05/10/2023-09936/temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled

Last verified: 2026-08-31. Review by: 2026-10-30.
Part of [DEA telemedicine controlled-substance prescribing flexibility -- extension history](https://referencesource.org/dea-telemedicine-prescribing-flexibility-extensions/).